3760 days ago
Speciality pharmaceutical company, Alliance Pharma (APH) last week announced that “turnover for 2013 is expected to be £45.5m (2012: £44.9m) and pre-tax profits are expected to be in line with current market expectations” (expectations are for earnings per share of around 3.5p) as well as an acquisition of the rights to the thyroid product Irenat in Germany from subsidiaries of Bayer AG.
In the 12 months to October 2013, total sales of Irenat by Bayer were €0.8 million and the gross margin generated was €0.5 million – with the company emphasising that “the acquisition, our first in Germany, will be immediately earnings enhancing and fits well with our strategy of building Alliance's international sales”. No acquisition price was provided though house broker, Numis, estimates £1.2 million.
Also positively,
